Immunicum AB (STO:IMMU), a biopharmaceutical company developing therapeutic cancer vaccines, reported on Thursday a change in the number of shares and votes in the company, as a result of the implementation of a share issue with preferential rights for the company's existing shareholders.
Under this rights issue, the number of shares and votes have increased by 20,383,412, which has increased the company's share capital by SEK 1,019,170.60.
As of 31 January 2019, the total share capital in Immunicum amounts to SEK4,612,876.55 and the total number of shares and votes amount to 92,257,531.
(EUR1.00=SEK10.36)
Virbac expands presence in Japan with Sasaeah acquisition
Pfizer reveals strong efficacy data for ABRYSVO in older adults against RSV
US CDC advisory committee backs Valneva's chikungunya vaccine
Takeda and Biological E. Limited join forces to combat global dengue threat
SK bioscience 'SKYTyphoid' receives WHO prequalification certification
ImmunityBio advances cancer vaccine trial for Lynch syndrome participants
AstraZeneca boosts vaccine portfolio with acquisition of Icosavax
Ultimovacs gains EMA Orphan Drug status for UV1 cancer vaccine in mesothelioma